Zyoxel Announces the Performance of Tests by Sanofi on the Power of 3D Liver Culture Models for More Predictive and Insightful DMPK Studies
OXFORD, England — Zyoxel, the world’s leading expert for advanced in vitro 3D liver models for drug discovery and drug testing, has announced preliminary results from a testing by Sanofi on Zyoxel’s LiverChip™ platform for drug metabolism and pharmacokinetic (DMPK) studies. Sanofi employed a variety of morphological, genetic and functional analyses to fully characterise the LiverChip™ system, the full findings of which will be presented as part of Zyoxel’s In Vitro Liver Technology Symposium taking place on December 10, 2013 in Oxford, UK.
Under the terms of an Equipment Hire Agreement, Sanofi, an integrated global healthcare leader, has been exploring the utility of Zyoxel’s LiverChip™ platform. During the project, which commenced in December 2012 and involved the installation of a LiverChip™ device at a Sanofi research site, the company tested the human hepatocyte LiverChip™ system against current industry gold standard 2D plated cultures of primary hepatocytes.
Using LiverChip™, Sanofi’s researchers were able to perform in depth DMPK analyses over much longer time courses of up to 6 days, including the accurate monitoring of dose clearance by the cytochrome P450 enzyme superfamily (CYPs), as well as the induction of CYP isoforms during drug metabolism. The study also confirmed that LiverChip™ does not suffer from any non-specific drug binding, while the results exhibited good reproducibility, both within individual plates and between replicate experiments.
For further details about the LiverChip™ technology, please visit Zyoxel’s website.
About Zyoxel
Zyoxel has developed and fully commercialized the world’s most physiologically accurate in vitro 3D liver model. Their products and services are used by pharmaceutical companies to predict the clinical safety and pharmacological properties of new drugs. Zyoxel’s platform is based upon innovative technologies developed at the University of Oxford and the Massachusetts Institute of Technology. The company was spun out of Oxford University’s Institute of Biomedical Engineering in 2009 with investment from Hong Kong multinational CN Innovations Holdings.
Contacts
Commercial Enquiries
Zyoxel Ltd
Ian Taylor
Sales
+44 (0) 7554 446 185
ian.taylor@zyoxel.com
www.zyoxel.com
or
Media Enquiries
Chempetitive Group (UK office)
Sam Marsden
Account Manager
+44 (0) 1223 828 200
smarsden@chempetitive.com
www.chempetitive.com

